Research programme: age-related macular degeneration therapeutic - Alnylam

Drug Profile

Research programme: age-related macular degeneration therapeutic - Alnylam

Alternative Names: ALN-VEG01

Latest Information Update: 16 Nov 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Age-related macular degeneration

Most Recent Events

  • 06 Jul 2006 This programme is available for licensing (
  • 01 Mar 2005 Preclinical data from a media release have been added to the Eye Disorders pharmacodynamics section
  • 30 Jun 2004 Preclinical trials in Age-related macular degeneration in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top